KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accumulated Expenses (2016 - 2025)

Nektar Therapeutics has reported Accumulated Expenses over the past 16 years, most recently at $22.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $22.3 million for Q4 2025, down 25.69% from a year ago — trailing twelve months through Dec 2025 was $22.3 million (down 25.69% YoY), and the annual figure for FY2025 was $22.3 million, down 25.69%.
  • Accumulated Expenses for Q4 2025 was $22.3 million at Nektar Therapeutics, down from $28.6 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for NKTR hit a ceiling of $37.4 million in Q1 2023 and a floor of $5.0 million in Q1 2025.
  • Median Accumulated Expenses over the past 5 years was $23.9 million (2021), compared with a mean of $22.4 million.
  • Peak annual rise in Accumulated Expenses hit 308.08% in 2025, while the deepest fall reached 79.3% in 2025.
  • Nektar Therapeutics' Accumulated Expenses stood at $15.7 million in 2021, then surged by 132.33% to $36.6 million in 2022, then tumbled by 39.38% to $22.2 million in 2023, then surged by 35.24% to $30.0 million in 2024, then fell by 25.69% to $22.3 million in 2025.
  • The last three reported values for Accumulated Expenses were $22.3 million (Q4 2025), $28.6 million (Q3 2025), and $6.5 million (Q2 2025) per Business Quant data.